Spero Therapeutics Hits New 52-Week Low at $1.37 Amid Market Volatility

Spero Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.37 on July 21, 2026. This decline marks a significant point in the company's performance, reflecting a 3.5% decrease over the past year, contrasting sharply with the S&P 500's gain of 19.09% during the same period. With a market capitalization of USD 135 million, Spero Therapeutics operates within a competitive industry landscape. The company's price-to-earnings (P/E) ratio stands at 14.00, indicating its current valuation relative to earnings. Notably, Spero Therapeutics does not offer a dividend, and its debt-to-equity ratio is reported at -0.65, suggesting a unique financial structure. The return on equity is recorded at 15.96%, while the price-to-book ratio is 2.29. As Spero Therapeutics navigates its current market position, the recent low price may prompt a reevaluation of its strategies and operational focus within the biotechnology field.